Literature DB >> 7965704

Diffusion of morphine-6-beta-D-glucuronide into the neonatal guinea pig brain during drug-induced respiratory depression.

L J Murphey1, G D Olsen.   

Abstract

Morphine-6-beta-D-glucuronide (M6G) is an active metabolite of morphine. In a previous study, M6G depressed respiration in the neonatal guinea pig, becoming more potent with aging, a finding that is confirmed in the current study. After s.c. injection, M6G is absorbed into plasma, crosses the blood-brain barrier and is present in the central nervous system at the time of maximal M6G-induced ventilatory depression. No hydrolysis of M6G to morphine is detected in either plasma or brain tissue by high-performance liquid chromatography. About 30% more M6G is in plasma in 3-day-old than in 7-day-old pups after drug administration (P < .05). Mean brain concentrations of M6G are 12% higher on day 3 than day 7, but the difference is not statistically significant. Brain-to-plasma ratios of M6G do not differ after 5 or 15 mg/kg of M6G or with age (mean ratio = 0.037). Brain drug concentration is a linear function of plasma drug levels (r2 = 0.84), suggesting M6G crosses the blood brain barrier by diffusion. Differential systemic absorption or central nervous system distribution of M6G cannot explain enhanced respiratory depression with aging. Morphine-3-beta-D-glucuronide (M3G) also crossed the blood-brain barrier, but is less permeable than M6G (mean brain-to-plasma ratio = 0.022). Contrary to reports in the literature, M3G at a dose of 75 mg/kg, does not stimulate respiration in this study. Morphine administration to neonatal guinea pigs produces measurable plasma and brain levels of M6G and M3G.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965704

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport.

Authors:  R Xie; M R Bouw; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.

Authors:  F Stain-Texier; G Boschi; P Sandouk; J M Scherrmann
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.

Authors:  J Huwyler; J Drewe; C Klusemann; G Fricker
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.

Authors:  R Xie; M Hammarlund-Udenaes; A G de Boer; E C de Lange
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

6.  Respiratory effects of chronic in utero methadone or morphine exposure in the neonatal guinea pig.

Authors:  Rosemary T Nettleton; Michael Wallisch; George D Olsen
Journal:  Neurotoxicol Teratol       Date:  2008-03-21       Impact factor: 3.763

Review 7.  Advances in the Physicochemical Profiling of Opioid Compounds of Therapeutic Interest.

Authors:  Károly Mazák; Béla Noszál; Sándor Hosztafi
Journal:  ChemistryOpen       Date:  2019-07-04       Impact factor: 2.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.